SCHEDULE 13D/A Filed 2026-06-01 Event 2026-05-28 SEC 0000947871-26-000592 →

ORBIMED ADVISORS LLC → Q32 Bio Inc. QTTB

Stake: — Shares: 4,127,987 Class: COMMON STOCK

Composite Decision Signal · PASS (LOW BASE-RATE EDGE) Conviction Score: 25/100 · Filer 90d Win Rate: 25% · Hist. 90d Edge: -5.4%

Filer track record (12 filings): 25% 90d win rate, +0.0% 90d edge
Elevated short days-to-cover (5.3 DTC)
Short interest building (+21.0% vs prior settlement)

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

0 transactions

0 buys · 0 sales · 0 awards/exercises

Issuer Cluster

9 13D/G filings on this issuer

8 other filings besides this one

Filer Track Record

145 filings by this filer

144 other filings in the data moat

Short Interest · settle 2026-10-15

DTC 5.25

5,652,682 shares short · +21.0% vs prior

Post-Filing Returns · since 2026-05-28 on QTTB

+1 day

0.0%

+5 days

0.0%

+30 days

0.0%

+60 days

+11.7%

+90 days

—

+180 days

—

Anchor price 13.62 on closest trading day on/after 2026-05-28. Source: Yahoo Finance daily adj_close (split + dividend adjusted).

Other 13D/G Filings on Q32 Bio Inc.

Filed	Form	Filer	Stake	Shares
2026-10-09	SCHEDULE 13G	Frazier Life Sciences Public Fund, L.P.	—	—	view →
2026-07-20	SCHEDULE 13D/A	ORBIMED ADVISORS LLC	—	4,127,987	view →
2026-07-10	SCHEDULE 13G	Boxer Capital Management, LLC	—	—	view →
2026-06-04	SCHEDULE 13G	BIOTECHNOLOGY VALUE FUND L P	—	—	view →
2026-05-28	SCHEDULE 13D/A	Atlas Venture Fund X, L.P.	3.60%	864,261	view →
2020-04-20	SC	Flynn James E	—	—	view →
2020-01-31	SC	Flynn James E	—	—	view →
2019-12-30	SC	Flynn James E	—	—	view →

Other Filings by ORBIMED ADVISORS LLC

Filed	Form	Issuer	Stake	Shares
2026-10-08	SCHEDULE 13D/A	ArriVent BioPharma, Inc.	5.80%	2,875,962	view →
2026-10-02	SCHEDULE 13D	ADARx Pharmaceuticals, Inc.	14.00%	14,913,764	view →
2026-09-25	SCHEDULE 13D	Electra Therapeutics, Inc.	11.00%	6,885,170	view →
2026-09-10	SCHEDULE 13D/A	Braveheart Bio, Inc.	13.50%	12,175,159	view →
2026-08-18	SCHEDULE 13D	BlossomHill Therapeutics, Inc.	8.90%	2,714,279	view →
2026-08-18	SCHEDULE 13D	Braveheart Bio, Inc.	17.20%	12,175,159	view →
2026-08-10	SCHEDULE 13D/A	MBX Biosciences, Inc.	—	3,074,853	view →
2026-08-05	SCHEDULE 13D	Yarrow Bioscience, Inc.	9.97%	266,306	view →
2026-07-29	SCHEDULE 13D	Scribe Therapeutics, Inc.	7.20%	1,348,825	view →
2026-07-20	SCHEDULE 13D/A	Q32 Bio Inc.	—	4,127,987	view →
2026-06-24	SCHEDULE 13D/A	Enliven Therapeutics, Inc. ELVN	—	6,774,507	view →
2026-06-17	SCHEDULE 13D/A	Enliven Therapeutics, Inc. ELVN	10.93%	7,634,630	view →
2026-06-15	SCHEDULE 13D/A	Shattuck Labs, Inc. STTK	—	9,021,127	view →
2026-04-10	SCHEDULE 13D/A	Adicet Bio, Inc. ACET	8.80%	844,787	view →
2026-01-27	SCHEDULE	Corvus Pharmaceuticals, Inc. CRVS	10.30%	8,609,091	view →
2025-10-10	SCHEDULE	Adicet Bio, Inc. ACET	9.60%	14,772,598	view →
2025-09-30	SCHEDULE	MBX Biosciences, Inc. MBX	9.00%	4,002,887	view →
2025-07-21	SCHEDULE	Passage BIO, Inc. PASG	7.82%	243,878	view →
2025-05-14	SCHEDULE	Corvus Pharmaceuticals, Inc. CRVS	12.20%	9,785,423	view →
2025-04-11	SCHEDULE	Compass Therapeutics, Inc. CMPX	11.00%	15,219,994	view →

Showing 20 of 144

Want this depth on every filing the moment it hits SEC EDGAR?

Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.

See pricing →